No registrations found.
ID
Source
Brief title
Health condition
many local and systemic side effects of anti glaucoma eye drops can be eliminated by using laser and reducing eye drops
Sponsors and support
Intervention
Outcome measures
Primary outcome
1, IOP lowering effect of SLT
Secondary outcome
1, inflammatory parameters after SLT ( redness, pain, cells in anterior chamber, IOP spike)
2, quality of life parameters
Background summary
Glaucoma is a very common chronic disease. Selective laser trabeculoplasty (SLT) has the advantage of eliminating the side effects that are very common after using anti-glaucoma eye drops. We aim to investigate several aspects of SLT
Study objective
1. does pseudophakia influence intra ocular pressure (IOP) lowering effect of SLT?
2. the effect of SLT relies on an inflammatory reaction. Anti-inflammatory therapy is often used immediately following SLT, does this influence the IOP lowering effect or the side effects after SLT?
3. anti-glaucoma eye drops have a lot of side effects. Does SLT improve quality of life by reducing number of eye medications?
4. is there a significant difference in IOP lowering effect of SLT in low, normal or high tension glaucoma?
Study design
start, 1 hour, 1 week, 1, 3, 6 and 12 months after SLT
Intervention
1,Randomization decides whether patients receive SLT or continue on drops.
2,In those to receive SLT, randomization decides whether indomethacin or dexamethasone drops are given after SLT.
3,SLT is applied in both eyes, randomization decides in which eye the anti-inflammatory therapy (indomethacin or dexamethasone) is given, we start SLT always at the right eye.
4, SLT is performed, right eye first, the week after that, the other eye is treated. Eye that does not receive anti-inflammatory therapy is control eye.
Inclusion criteria
patients with ocular hypertension or chronic open angle glaucoma controlled by medical therapy. Patients had to be prepared to sign an informed consent document.
Exclusion criteria
other types of glaucoma than open angle glaucoma, previous trabeculectomy or selective laser trabeculoplasty. Corneal disease that inhibit good visualization of the trabecular meshwork and patients taking systemic steroids are excluded
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5308 |
| NTR-old | NTR5417 |
| Other | MEC : 4313 |